Strauer B E
Department of Medicine, University of Düsseldorf, F.R.G.
J Cardiovasc Pharmacol. 1988;12 Suppl 4:S45-54. doi: 10.1097/00005344-198806124-00009.
In essential hypertension, ventricular function is determined primarily by the degree of hypertrophy (myocardial factor) and by the organic complications in the coronary artery (coronary factor). Ventricular function is inversely correlated with ventricular size and systolic wall stress, inasmuch as ventricular function diminishes when these two variables increase. Coronary reserve is reduced even in hypertensive hypertrophy without evidence of coronary artery disease. MVO2 per mass unit is directly correlated with systolic wall stress per cross-sectional area of the left ventricular wall. It is concluded that the appropriateness of left ventricular hypertrophy, as a result of mass-to-volume ratio and stress, is a major determinant of left ventricular performance, of coronary blood flow, and of myocardial oxygen consumption. Pharmacotherapeutical means of reversing cardiac hypertrophy (prazosin, clonidine, enalapril, and nifedipine) were analyzed in concentrically, as well as eccentrically, hypertrophied left ventricles. Regression of cardiac hypertrophy, i.e., therapeutic intervention on a critical precursor of hypertensive congestive heart failure, can be obtained by various antihypertensive agents. Prazosin, calcium channel blockers, and angiotensin converting enzyme inhibitors as well as a combined treatment regimen using alpha-receptor blockers together with diuretics and vasodilators can all induce regression of hypertrophy associated with an improvement in left ventricular function. Moreover, an improved coronary reserve may reduce the ischemic risk of the hypertrophied myocardium. However, not all antihypertensive drugs seem equally effective in bringing about coronary regression of left ventricular hypertrophy (LVH). No regression or little regression has been found with diuretic monotherapy despite a satisfactory reduction in blood pressure. On the other hand, a trend towards a regression has been observed in patients in whom treatment with clonidine significantly reduced catecholamines. Recent experimental data in spontaneously hypertensive rats indicate that the impaired coronary reserve can be significantly improved by the long-term administration of blood pressure lowering agents, e.g., by nifedipine or by the combination of metoprolol plus hydralazine.
在原发性高血压中,心室功能主要由肥厚程度(心肌因素)和冠状动脉器质性并发症(冠脉因素)决定。心室功能与心室大小和收缩期室壁应力呈负相关,因为当这两个变量增加时心室功能会降低。即使在无冠状动脉疾病证据的高血压性肥厚中,冠脉储备也会降低。每单位质量的心肌耗氧量(MVO2)与左心室壁每横截面积的收缩期室壁应力直接相关。得出的结论是,左心室肥厚的适宜性,基于质量与容积比和应力,是左心室功能、冠脉血流量和心肌耗氧量的主要决定因素。对向心性和离心性肥厚的左心室分析了逆转心脏肥厚的药物治疗方法(哌唑嗪、可乐定、依那普利和硝苯地平)。心脏肥厚的消退,即对高血压性充血性心力衰竭关键前驱因素的治疗干预,可通过多种抗高血压药物实现。哌唑嗪、钙通道阻滞剂、血管紧张素转换酶抑制剂以及使用α受体阻滞剂联合利尿剂和血管扩张剂的联合治疗方案均可诱导肥厚消退并改善左心室功能。此外,改善的冠脉储备可能降低肥厚心肌的缺血风险。然而,并非所有抗高血压药物在使左心室肥厚(LVH)发生冠脉消退方面似乎都同样有效。尽管血压得到令人满意的降低,但利尿剂单一疗法未发现消退或仅有轻微消退。另一方面,在可乐定治疗使儿茶酚胺显著降低的患者中观察到有消退的趋势。自发性高血压大鼠的近期实验数据表明,长期给予降压药,如硝苯地平或美托洛尔加肼屈嗪的联合用药,可显著改善受损的冠脉储备。